戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 n the Randomized Aldactone Evaluation Study (RALES).
2 ironolactone initiation after publication of RALES.
3 eased >7-fold (3.0% to 21.3% P<0.0001) after RALES.
4                   Of all prescriptions after RALES, 30.9% were provided to patients not meeting enrol
5 emia, low systolic blood pressure, pulmonary rales above the bases, or an exacerbation of known ische
6 n physical signs are tachypnea, tachycardia, rales, and cyanosis.
7  increased markedly after the publication of RALES, and many treated patients were at risk for hyperk
8 ia and worsening renal function were rare in RALES, but laboratory monitoring was frequent.
9 ngham Criteria variables (dyspnea, pulmonary rales, cardiomegaly, interstitial or pulmonary edema on
10 n findings typical of interstitial fibrosis (rales, clubbing, or cyanosis) raised the risk of subsequ
11 r the Randomized Aldactone Evaluation Study (RALES) demonstrated a 30% mortality benefit for treating
12 ly 2000 to June 2001, n=9468) publication of RALES in September 1999.
13 f the Randomized Aldactone Evaluation Study (RALES) in national cohorts of older patients hospitalize
14 confidence interval {CI}, 1.2-4.1]), to have rales on examination (OR, 1.9 [95% CI, 1.0-3.7]), to be
15                                              Rales on initial examination were associated with early
16 istory of stroke, clinical heart failure and rales on physical exam.
17 ase, atrial fibrillation, diabetes mellitus, rales, peripheral edema, higher New York Heart Associati
18                        We used data from the RALES (Randomized Aldactone Evaluation Study) in 1,658 p
19                                          The RALES study showed that spironolactone, added to convent
20    Clinical follow-up does not adhere to the RALES trial guidelines, resulting in higher complication
21  setting, we analyzed the application of the RALES trial protocol to the care of 104 patients, whom w
22 h spironolactone treatment compared with the RALES trial.
23 pironolactone for HF after prerelease of the RALES trial.
24 n the Randomized Aldactone Evaluation Study (RALES) trial.
25 (Randomized Spironolactone Evaluation Study [RALES] trial), we noted a marked increase in widespread

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。